JP6909795B2 - 胃癌の検出および治療のための組成物および方法 - Google Patents

胃癌の検出および治療のための組成物および方法 Download PDF

Info

Publication number
JP6909795B2
JP6909795B2 JP2018534924A JP2018534924A JP6909795B2 JP 6909795 B2 JP6909795 B2 JP 6909795B2 JP 2018534924 A JP2018534924 A JP 2018534924A JP 2018534924 A JP2018534924 A JP 2018534924A JP 6909795 B2 JP6909795 B2 JP 6909795B2
Authority
JP
Japan
Prior art keywords
cdr
antibody
progastrin
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505784A5 (enExample
JP2019505784A (ja
Inventor
アレクサンドル、プリュール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progastrine et Cancers SARL
Original Assignee
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine et Cancers SARL filed Critical Progastrine et Cancers SARL
Publication of JP2019505784A publication Critical patent/JP2019505784A/ja
Publication of JP2019505784A5 publication Critical patent/JP2019505784A5/ja
Priority to JP2021110785A priority Critical patent/JP7478708B2/ja
Application granted granted Critical
Publication of JP6909795B2 publication Critical patent/JP6909795B2/ja
Priority to JP2024006496A priority patent/JP2024041982A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018534924A 2015-12-31 2017-01-02 胃癌の検出および治療のための組成物および方法 Active JP6909795B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021110785A JP7478708B2 (ja) 2015-12-31 2021-07-02 胃癌の検出および治療のための組成物および方法
JP2024006496A JP2024041982A (ja) 2015-12-31 2024-01-19 胃癌の検出および治療のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15307191.5 2015-12-31
EP15307191 2015-12-31
EP16305131 2016-02-05
EP16305131.1 2016-02-05
PCT/EP2017/050036 WO2017114975A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating gastric cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110785A Division JP7478708B2 (ja) 2015-12-31 2021-07-02 胃癌の検出および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019505784A JP2019505784A (ja) 2019-02-28
JP2019505784A5 JP2019505784A5 (enExample) 2019-06-06
JP6909795B2 true JP6909795B2 (ja) 2021-07-28

Family

ID=57821945

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018534924A Active JP6909795B2 (ja) 2015-12-31 2017-01-02 胃癌の検出および治療のための組成物および方法
JP2021110785A Active JP7478708B2 (ja) 2015-12-31 2021-07-02 胃癌の検出および治療のための組成物および方法
JP2024006496A Withdrawn JP2024041982A (ja) 2015-12-31 2024-01-19 胃癌の検出および治療のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021110785A Active JP7478708B2 (ja) 2015-12-31 2021-07-02 胃癌の検出および治療のための組成物および方法
JP2024006496A Withdrawn JP2024041982A (ja) 2015-12-31 2024-01-19 胃癌の検出および治療のための組成物および方法

Country Status (12)

Country Link
US (2) US12474343B2 (enExample)
EP (2) EP3954998B1 (enExample)
JP (3) JP6909795B2 (enExample)
KR (2) KR102477179B1 (enExample)
CN (1) CN108700588A (enExample)
AU (2) AU2017204685B2 (enExample)
BR (1) BR112018013268A2 (enExample)
CA (2) CA3193501A1 (enExample)
EA (1) EA037027B1 (enExample)
ES (2) ES3011729T3 (enExample)
SG (1) SG11201805141QA (enExample)
WO (1) WO2017114975A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
KR102379022B1 (ko) 2019-05-24 2022-03-28 주식회사 엠디헬스케어 qPCR 분석을 통한 위암 진단방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
FI20011908L (fi) 2001-09-28 2003-03-29 Biohit Oyj Menetelmä vatsasyövän osoittamiseksi
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
CN101797382B (zh) * 2010-03-03 2013-11-20 戚胜美 抗人前胃液素多肽免疫组合物
US8674064B2 (en) 2010-03-03 2014-03-18 Onkologix Ltd Immunogenic compositions against human progastrin peptides
WO2011116954A2 (en) 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
ES2899360T3 (es) 2022-03-11
EP3954998B1 (en) 2024-12-25
EP3954998C0 (en) 2024-12-25
US20190011449A1 (en) 2019-01-10
WO2017114975A1 (en) 2017-07-06
KR20180105642A (ko) 2018-09-28
CA3193501A1 (en) 2017-07-06
AU2022263503B2 (en) 2025-01-23
JP7478708B2 (ja) 2024-05-07
BR112018013268A2 (pt) 2018-12-11
KR102477179B1 (ko) 2022-12-13
ES3011729T3 (en) 2025-04-08
EP3954998A1 (en) 2022-02-16
KR102428255B1 (ko) 2022-08-03
JP2021167831A (ja) 2021-10-21
AU2017204685A1 (en) 2018-07-12
AU2022263503A1 (en) 2022-12-08
US12474343B2 (en) 2025-11-18
JP2024041982A (ja) 2024-03-27
EA037027B1 (ru) 2021-01-27
AU2017204685B2 (en) 2022-10-13
SG11201805141QA (en) 2018-07-30
JP2019505784A (ja) 2019-02-28
US20240402181A1 (en) 2024-12-05
EA201891528A1 (ru) 2019-01-31
CN108700588A (zh) 2018-10-23
KR20220100099A (ko) 2022-07-14
CA3009740A1 (en) 2017-07-06
EP3397966B1 (en) 2021-09-29
EP3397966A1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
JP7363007B2 (ja) 食道癌の検出および治療のための組成物および方法
JP7279761B2 (ja) 卵巣癌の検出および治療のための組成物および方法
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
US20240018264A1 (en) Compositions and methods for detecting and treating ovarian cancer
EA050244B1 (ru) Способ диагностики in vitro рака желудка и способ мониторинга эффективности его лечения
EA050261B1 (ru) Способ in vitro диагностики рака яичников и способ мониторинга эффективности его лечения

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210705

R150 Certificate of patent or registration of utility model

Ref document number: 6909795

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250